Piche, T, Vanbiervliet, G, Cherikh, F et al. · Gut · 2005 · DOI
This study tested whether a medication called ondansetron, which affects serotonin in the brain, could reduce fatigue in people with chronic hepatitis C. Thirty-six patients took either ondansetron or a placebo pill for one month and were then observed for another month. Ondansetron significantly improved fatigue scores by more than 30% within two weeks and maintained this improvement, while placebo did not.
This study is relevant to ME/CFS research because it demonstrates that serotonergic pathways may contribute to fatigue in chronic diseases, a mechanism potentially applicable to ME/CFS. The authors cite prior evidence of ondansetron efficacy in chronic fatigue syndrome, suggesting a common biological pathway in fatigue syndromes. Understanding these pathways could open new therapeutic avenues for ME/CFS patients who currently lack effective fatigue treatments.
This study does not prove that ondansetron is effective for ME/CFS fatigue—it was conducted in hepatitis C patients, a different disease with different pathophysiology. The mechanism of fatigue reduction remains unclear; serotonergic involvement is inferred but not directly measured. Results cannot be extrapolated to ME/CFS without dedicated trials in that population, as fatigue in different conditions may involve distinct biological mechanisms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →